<DOC>
	<DOC>NCT00691392</DOC>
	<brief_summary>This is a one-period, double-blind, single-center pharmacokinetic study of linezolid in patients with MDR or XDR tuberculosis treated with linezolid and an Optimized Background Therapy (defined as treatment with &gt; 4 drugs with activity against tuberculosis to which the patient's isolate is believed to be sensitive by history or based on drug sensitivity testing).</brief_summary>
	<brief_title>Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)</brief_title>
	<detailed_description>This is a one-period, double-blind, single-center pharmacokinetic study of linezolid in patients with MDR or XDR tuberculosis treated with linezolid and an Optimized Background Therapy (defined as treatment with &gt; 4 drugs with activity against tuberculosis to which the patient's isolate is believed to be sensitive by history or based on drug sensitivity testing).</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
	<mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Enrolled in the TBTC Study 30 Provision of informed consent for the study Severe anemia as defined by a hematocrit less than 25% (most recent value, measured within 30 days of the PK study).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Multi-Drug Resistant Tuberculosis</keyword>
	<keyword>Extensively Drug Resistant Tuberculosis</keyword>
	<keyword>MDR TB</keyword>
	<keyword>XDR TB</keyword>
	<keyword>MDR</keyword>
	<keyword>XDR</keyword>
</DOC>